Abstract
Objectives: To compare the effect of a soy rich diet and hormone replacement therapy (HRT) on
the main biomarkers of bone turnover and bone mineral density (BMD) at postmenopausal
age. Methods: 187 healthy asymptomatic postmenopausal women, aged 39–60, were recruited and randomized
into a soy rich diet group, a HRT group, and a control group. Bone biomarkers and
BMD were evaluated at baseline and after 6 months at the end of the study. Results: Diet is not as effective as HRT in reducing the postmenopausal turnover; however
diet stimulates bone osteoblastic activity, as evidenced by significant increase in
osteocalcin concentrations. BMD decreases significantly only in the control group,
but not in the intervention groups. Conclusions: Our data suggest that soy products could be effective in reducing the risk of osteoporosis
in asymptomatic postmenopausal women, but our findings should be confirmed before
recommending the diet as a valid alternative to HRT.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to MaturitasAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Pathogenesis of osteoporosis.The Lancet. 1993; 341: 797-805
- The menopause and the skeleton: key issues.Baillière's Clin. Obstet. Genaecol. 1996; 10: 469-481
- Long term prevention of postmenopausal osteoporosis by oestrogen: evidence for an increased bone mass after delayed onset of oestrogen treatment.Lancet. 1976; 1: 1038-1041
- Hip fracture and the use of estrogens in postmenopausal women. The Framingham study.N. Engl. J. Med. 1987; 317: 1169-1174
- Bone response to termination of oestrogen treatment.Lancet. 1978; 1: 1325-1327
- Treatment of osteoporosis in elderly women.Am. J. Med. 1995; S2A: 60-66
- The effect of postmenopausal estrogen therapy on bone density in elderly women.N. Engl. J. Med. 1993; 329: 1141-1146
- Cardiovascular risk and use of estrogens or estrogen-progestagen combinations. Stanford three-community study.JAMA. 1976; 235: 811-815
Surgically confirmed gallbladder disease, venous thromboembolism, and breast tumors in relation to postmenopusal estrogen therapy. A report from the Boston Collaborative Drug Surveillance Program. Boston University Medical Center. N Engl J Med 1974;290:15–19.
- Breast cancer and hormone replacement therapy; collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer.Lancet. 1997; 350: 1047-1059
- Long term consequences of estrogen and estrogen-progestinreplacement.Cancer Causes Control. 1992; 3: 83-90
- Soy protein and isoflavones: their efects on blood lipids and bone density in postmenopausal women.Am. J. Clin. Nutr. 1998; 68: 1375S-1379S
- Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenoapusal women.Am. J. Clin. Nutr. 2000; 72: 844-852
- Effect of soy protein on bone metabolism in postmenopausal Japanese women.Osteoporos Int. 2000; 11: 721-724
- Effects of soy isoflavones on markers of bone turnover in premenopausal and postmenopausal women.JCEM. 2000; 85: 3043-3048
- Soy isoflavones supplementation in postmenopausal women. Effects on plasma lipids, antioxidant enzyme activities and bone density.J. Reprod. Med. 2001; 46: 221-226
- The effects of a soy rich diet on serum lipids: the Menfis randomized trial.Maturitas. 2002; 41: 97-104
- Expression and localization of estrogen receptor β in murine and humane bone.J. Bone Miner. Res. 1999; 14: 923-929
- Demonstration of estrogen receptor β immunoreactivity in human growth plate cartilage.J. Clin. Endocrinol. Metab. 1999; 84: 370-373
- Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β.Endocrinology. 1998; 139: 4259-4263
- Novel aspects of estrogen action.J. Soc. Gynecol. Investig. 2000; 7: S8-S9
- Isoflavones and postmenopausal bone health: a viable alternative to estrogen to estrogen therapy?.Menopause. 1999; 6: 233-241
- Ipriflavone prevents the mass reduction in premenopausal women treated with gonadotropin hormone-releasing hormone agonists.Bone Miner. 1994; 26: 19-26
- Effect of ipriflavone on osteoporosis induced by ovariectomy in rats.J. Bone Miner. Metab. 1986; 3: 205-210
- Effect of ipriflavone on glucocorticoid-induced osteoporosis in rats.Life Sci. 1986; 38: 951-958
- Treatment of bone loss in oophorectomized women with a combination of ipriflavone and conjugated equine estrogen.Int. J. Gynaecol. Obstet. 1998; 62: 69-75
- Role of soy protein with normal or reduced isoflavones content in reversing bone loss induced by ovarian hormone deficiency in rats.Am. J. Clin. Nutr. 1998; 68: 1358S-1363S
- Dietary soybean protein prevents bone loss in an ovariectomized rat model of osteoporosis.J. Nutr. 1996; 126: 161-167
- Evaluation of the effect of soybean milk and soybean peptide on bone metabolism in the rat model with ovariectomized osteoporosis.J. Nutr. Sci. Vitamino. (Tokyo). 1994; 40 (Abstract): 201-211
- Soyfoods, soybean isoflavones, and bone health: a brief overview.J. Ren. Nutr. 2000; 10: 63-68
Article info
Publication history
Accepted:
April 5,
2002
Received in revised form:
March 20,
2002
Received:
August 23,
2001
Identification
Copyright
© 2002 Elsevier Science Ireland Ltd. Published by Elsevier Inc. All rights reserved.
